Workflow
圣诺生物:前三季度净利同比预增101%—145%

Core Viewpoint - Shengnuo Bio (688117) expects a significant increase in net profit for the first three quarters of 2025, projecting a profit of between 114 million to 140 million yuan, representing a year-on-year growth of 100.53% to 145.1% [1] Group 1 - The company's main business has shown stable development during the reporting period [1] - The construction of production capacity is gradually being realized, contributing to overall performance improvement [1] - The demand for orders in the peptide raw material business continues to grow, enhancing market competitiveness and sustainable profitability [1]